This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Eudendron S.r.l., Universita′ Degli Studi Di Milano. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: The Innovative Contributions of Fabio Zuccotto
Introduction
Fabio Zuccotto is a notable inventor based in Varese, Italy. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel therapeutic compounds. His work focuses on addressing critical health issues such as cancer and neurodegenerative diseases.
Latest Patents
Zuccotto holds a patent for "Heterocyclic derivatives modulating activity of certain protein kinases." This invention relates to novel heterocyclic derivatives characterized by a general formula (I) and their therapeutic applications for diseases including cancer, inflammation, pain, autoimmune diseases, and neurodegenerative disorders like Alzheimer's and Parkinson's disease. The compounds of formula (I) are particularly valuable for treating patients who do not respond to existing kinase inhibition therapies.
Career Highlights
Throughout his career, Fabio Zuccotto has worked with several esteemed organizations. He has been associated with Eudendron S.r.l., where he contributed to innovative research and development. Additionally, he has collaborated with the Università Degli Studi Di Milano, further enhancing his expertise in the field.
Collaborations
Zuccotto has worked alongside notable colleagues such as Mauro Angiolini and Anna Bernardi. Their collaborative efforts have contributed to advancing research in medicinal chemistry and therapeutic applications.
Conclusion
Fabio Zuccotto's innovative work in developing heterocyclic derivatives showcases his commitment to addressing significant health challenges. His contributions to the field of medicinal chemistry are noteworthy and continue to impact therapeutic strategies for various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile